The article describes Zoll Medical's LifeVest Wearable Defibrillator which was worn by patients at risk of sudden cardiac arrest. Chingping Wan, a medical doctor who tested LifeVest, has concluded that it is a cost-effective therapy to prevent sudden cardiac death of post-acute myocardial ...
Food and Drug Administration (FDA) to Zoll Medical of Chelmsford, Massachusetts to market and sell its fourth-generation LifeVest wearable defibrillator. The device allows the doctors of patients at risk for sudden cardiac arrest (SCA) to assess their long-term arrhythmic risk and make appropriate...
BackgroundAn implantable cardioverter defibrillator (ICD) is effective in preventing sudden cardiac death (SCD). Once an ICD is removed and reimplantation is not feasible, a wearable cardioverter defibrillator (WCD) may be an alternative option. We determined the effectiveness of WCD for SCD ...